Top Markets
Coin of the day
Apollomics, Inc. Apollomics, Inc.

Apollomics, Inc.

APLM
Rang in Aktien #25241
Apollomics, Inc., a biotechnology enterprise established in 2015 and... Apollomics, Inc., a biotechnology enterprise established in 2015 and headquartered in Foster City, California, conducts its research and development operations across California, Hangzhou, Shanghai, China, and Australia. The company is dedicated to discovering and advancing innovative oncology treatments to address critical unmet medical requirements. Its therapeutic pipeline features APL-101 (Vebreltinib), a potent and selective c-Met inhibitor being developed for non-small cell lung cancer and other advanced malignancies. Also in development is APL-102, an orally administered, small molecule multiple tyrosine kinase inhibitor intended for liver, breast, and esophageal cancers. Furthermore, APL-122 is an investigational tumor inhibitor candidate focused on treating cancers within the brain. The organization was formerly known as CBT Pharmaceuticals, Inc. before adopting the name Apollomics, Inc. in January 2019.
Aktienkurs
$23.57
Zuletzt synchronisiert: 2026-08-20
Marktkapitalisierung
$51.76M
Veränderung (1 Tag)
-0.08%
Veränderung (1 Jahr)
289.59%
Land
US
Handel Apollomics, Inc. (APLM)

Kategorie

Kursverlauf für Apollomics, Inc. (APLM)
Höchster Schlusskurs: $20.22 am 2026-08-01

Niedrigster Schlusskurs: $990.67 am 2021-11-01
Kursverlauf der Aktie von Apollomics, Inc. von 2021 bis 2026
Jährliche Kursentwicklung
Jahr Leistung
2026 (TTM) 0.80%
2025 83.86%
2024 -88.89%
2023 -91.94%
2022 3.60%
2021 0.00%
Aktienkurs vergleichbarer Unternehmen oder Wettbewerber
Unternehmen Aktienkurs Veränderung 1J% Land
$539.14 35.65%
US
$1.04K 56.21%
NL
$118.70 -18.24%
AU
$758.49 8.17%
CH
$130.43 397.46%
US